Sebastian Bauer: We must not give up on MDM2 inhibitors in LPS
Sebastian Bauer , Professor of Translational Oncology at the University of Duisburg-Essen, shared on X:
“We must not give up on MDM2 inhibitors in LPS. Despite a negative trial. The signal of targeting a tumor suppressor in Brightline is impressive. Given the universal presence of the genomic feature we should exploit combos or sequences. Chapeau to Patrick Schöffski. Great achievement.”
Herbert Loong, Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong (CUHK), shared this post on X, adding:
“Completely agree! This is ‘negative’ trial but a true ‘positive’ in understanding and contemporary evidence of treatment outcomes in a specific histology. Have come long way with more accurate diagnosis & supportive measures equally doubled the survival of patients compared with ‘historical’ control.”
More posts featuring Herbert Loong.
Dr. Herbert H. F. Loong is the Chair-Elect of the International Affairs Committee, a Scientific Track Member (2022-2024), and the Track Leader for Sarcoma (2023) at the American Society of Clinical Oncology (ASCO). Additionally, he has been promoted to Steering Committee Member at the Lung Cancer Policy Network.
Dr. Loong is also the Chairperson of the Asia Pacific Coalition against Lung Cancer, a Board Member of the Connective Tissue Oncology Society, and a Committee Member of the International Association for the Study of Lung Cancer. He is an Associate Professor in the Department of Clinical Oncology at The Chinese University of Hong Kong (CUHK).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023